Apollon Wealth Administration LLC lowered its stake in shares of Quest Diagnostics Included (NYSE:DGX – Free Report) by 10.4% through the third quarter, Holdings Channel.com studies. The agency owned 6,279 shares of the medical analysis firm’s inventory after promoting 732 shares through the quarter. Apollon Wealth Administration LLC’s holdings in Quest Diagnostics had been price $975,000 as of its most up-to-date SEC submitting.
A number of different institutional traders have additionally lately made modifications to their positions within the inventory. Mitsubishi UFJ Asset Administration Co. Ltd. elevated its place in shares of Quest Diagnostics by 16.5% through the first quarter. Mitsubishi UFJ Asset Administration Co. Ltd. now owns 131,329 shares of the medical analysis firm’s inventory price $17,481,000 after buying an extra 18,642 shares within the final quarter. Vanguard Group Inc. elevated its place in shares of Quest Diagnostics by 2.5% through the first quarter. Vanguard Group Inc. now owns 13,921,955 shares of the medical analysis firm’s inventory price $1,853,151,000 after buying an extra 345,754 shares within the final quarter. Seven Eight Capital LP purchased a brand new stake in shares of Quest Diagnostics through the first quarter price about $729,000. Janus Henderson Group PLC elevated its place in shares of Quest Diagnostics by 126.0% through the first quarter. Janus Henderson Group PLC now owns 37,305 shares of the medical analysis firm’s inventory price $4,966,000 after buying an extra 20,800 shares within the final quarter. Lastly, Harbor Capital Advisors Inc. elevated its place in shares of Quest Diagnostics by 292.5% through the second quarter. Harbor Capital Advisors Inc. now owns 4,733 shares of the medical analysis firm’s inventory price $648,000 after buying an extra 3,527 shares within the final quarter. Institutional traders and hedge funds personal 88.06% of the corporate’s inventory.
Wall Avenue Analyst Weigh In
A number of equities analysis analysts have lately commented on the inventory. Evercore ISI assumed protection on shares of Quest Diagnostics in a analysis report on Wednesday, August twenty eighth. They set an “in-line” ranking and a $165.00 goal worth for the corporate. UBS Group boosted their goal worth on shares of Quest Diagnostics from $165.00 to $166.00 and gave the inventory a “impartial” ranking in a analysis report on Wednesday, October twenty third. Piper Sandler elevated their worth goal on shares of Quest Diagnostics from $150.00 to $165.00 and gave the corporate a “impartial” ranking in a analysis be aware on Monday, October twenty eighth. Barclays boosted their goal worth on Quest Diagnostics from $154.00 to $168.00 and gave the inventory an “equal weight” ranking in a analysis be aware on Wednesday, October twenty third. Lastly, Citigroup elevated their worth goal on Quest Diagnostics from $165.00 to $185.00 and gave the corporate a “purchase” ranking in a analysis report on Wednesday, October twenty third. 9 equities analysis analysts have rated the inventory with a maintain ranking, 5 have given a purchase ranking and one has assigned a powerful purchase ranking to the corporate. In response to information from MarketBeat.com, the corporate has a consensus ranking of “Maintain” and a mean worth goal of $164.58.
Learn Our Newest Inventory Evaluation on DGX
Insider Shopping for and Promoting at Quest Diagnostics
In different Quest Diagnostics information, SVP Karthik Kuppusamy offered 1,990 shares of Quest Diagnostics inventory in a transaction dated Wednesday, August twenty eighth. The inventory was offered at a mean worth of $153.26, for a complete transaction of $304,987.40. Following the completion of the transaction, the senior vp now owns 11,459 shares of the corporate’s inventory, valued at $1,756,206.34. The commerce was a 14.80 % lower of their place. The transaction was disclosed in a submitting with the Securities & Alternate Fee, which is out there by way of this hyperlink. Additionally, CAO Michael J. Deppe offered 18,755 shares of the inventory in a transaction dated Wednesday, November sixth. The inventory was offered at a mean worth of $154.05, for a complete transaction of $2,889,207.75. Following the completion of the sale, the chief accounting officer now instantly owns 34,941 shares within the firm, valued at roughly $5,382,661.05. The commerce was a 34.93 % lower of their possession of the inventory. The disclosure for this sale may be discovered right here. Insiders have offered 22,520 shares of firm inventory valued at $3,472,728 within the final 90 days. 0.79% of the inventory is at the moment owned by firm insiders.
Quest Diagnostics Inventory Efficiency
Shares of DGX opened at $160.39 on Friday. Quest Diagnostics Included has a 1 12 months low of $123.04 and a 1 12 months excessive of $162.59. The corporate has a debt-to-equity ratio of 0.83, a present ratio of 1.25 and a fast ratio of 1.17. The inventory’s fifty day shifting common worth is $153.84 and its two-hundred day shifting common worth is $147.26. The agency has a market cap of $17.90 billion, a PE ratio of 21.56, a PEG ratio of two.79 and a beta of 0.89.
Quest Diagnostics (NYSE:DGX – Get Free Report) final launched its quarterly earnings information on Tuesday, October twenty second. The medical analysis firm reported $2.30 EPS for the quarter, beating the consensus estimate of $2.26 by $0.04. The enterprise had income of $2.49 billion for the quarter, in comparison with the consensus estimate of $2.43 billion. Quest Diagnostics had a internet margin of 8.82% and a return on fairness of 15.25%. The corporate’s income was up 8.5% in comparison with the identical quarter final 12 months. Throughout the identical interval within the prior 12 months, the agency earned $2.22 earnings per share. On common, equities analysis analysts forecast that Quest Diagnostics Included will put up 8.9 EPS for the present 12 months.
Quest Diagnostics Pronounces Dividend
The agency additionally lately disclosed a quarterly dividend, which shall be paid on Wednesday, January twenty ninth. Traders of file on Tuesday, January 14th shall be paid a $0.75 dividend. The ex-dividend date is Tuesday, January 14th. This represents a $3.00 dividend on an annualized foundation and a yield of 1.87%. Quest Diagnostics’s dividend payout ratio is 40.32%.
Quest Diagnostics Firm Profile
Quest Diagnostics Included gives diagnostic testing and providers in the USA and internationally. The corporate develops and delivers diagnostic info providers, reminiscent of routine, non-routine and superior scientific testing, anatomic pathology testing, and different diagnostic info providers.
Learn Extra
Wish to see what different hedge funds are holding DGX? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Quest Diagnostics Included (NYSE:DGX – Free Report).
Obtain Information & Scores for Quest Diagnostics Every day – Enter your e mail tackle under to obtain a concise every day abstract of the most recent information and analysts’ scores for Quest Diagnostics and associated firms with MarketBeat.com’s FREE every day e mail publication.
